Plain Generics: Why the Market Rerates One | Economics, ROCE, why premiums persist 1.1.7 | Stock-Pickers Toolkit for GLP-1 / CDMO Names | Checklist + worked example (Divis/Syngene) 1.1.8 | Losers & Second-Order Effects of the GLP-1 Wave | Disrupted sectors, pricing caps, policy risk INVEST IN INDIA: GUIDE TO INDIAS FASTEST-GROWING SECTORS This newsletter provides deep-dive analysis of Indias highest-growth investment opportunities across 10 sectors and 200+ investment theses
The Neelakantan 2018 study reported that 5-Amino-1MQ administration to diet-induced obese mice produced reductions in adipose-tissue NNMT enzymatic activity, with concurrent reductions in fat mass and improvements in glucose tolerance [1]
For more information or to view current program details, visit the official Direct Meds website
Lisco and colleagues published a review of the risks of GLP-1s and thyroid cancer in the journal Endocrine Connections in 2023, and although they describe evidence for a risk of thyroid cancer, they conclude: It is reasonable to continue prescribing GLP-1RAs due to the evidence of more relevant and well-recognized antihyperglycemic, cardiovascular, and renal benefits, with the management staying within current recommendations. If you are considering taking a GLP-1 but are concerned about the risk of thyroid cancer, you should discuss it with your doctor
$54.99 $149.99Price range: $54.99 through $149.99 Molecular Formula: CHNO Description: RETA is a synthetic peptide that acts as a triple agonist, targeting the Glucagon-like peptide-1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP), and Glucagon (GCG) receptors
